RCUS
Price
$7.17
Change
-$0.72 (-9.13%)
Updated
Apr 3 closing price
Capitalization
758.88M
39 days until earnings call
XOMA
Price
$19.24
Change
-$0.57 (-2.88%)
Updated
Apr 4, 10:30 AM (EDT)
Capitalization
237.3M
39 days until earnings call
Ad is loading...

RCUS vs XOMA

Header iconRCUS vs XOMA Comparison
Open Charts RCUS vs XOMABanner chart's image
Arcus Biosciences
Price$7.17
Change-$0.72 (-9.13%)
Volume$2.07M
Capitalization758.88M
XOMA Royalty
Price$19.24
Change-$0.57 (-2.88%)
VolumeN/A
Capitalization237.3M
RCUS vs XOMA Comparison Chart
Loading...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RCUS vs. XOMA commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCUS is a StrongBuy and XOMA is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (RCUS: $7.17 vs. XOMA: $19.81)
Brand notoriety: RCUS and XOMA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCUS: 193% vs. XOMA: 147%
Market capitalization -- RCUS: $758.88M vs. XOMA: $237.3M
RCUS [@Biotechnology] is valued at $758.88M. XOMA’s [@Biotechnology] market capitalization is $237.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCUS’s FA Score shows that 0 FA rating(s) are green whileXOMA’s FA Score has 1 green FA rating(s).

  • RCUS’s FA Score: 0 green, 5 red.
  • XOMA’s FA Score: 1 green, 4 red.
According to our system of comparison, XOMA is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCUS’s TA Score shows that 4 TA indicator(s) are bullish while XOMA’s TA Score has 5 bullish TA indicator(s).

  • RCUS’s TA Score: 4 bullish, 3 bearish.
  • XOMA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, XOMA is a better buy in the short-term than RCUS.

Price Growth

RCUS (@Biotechnology) experienced а -15.55% price change this week, while XOMA (@Biotechnology) price change was -5.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

RCUS is expected to report earnings on May 13, 2025.

XOMA is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($759M) has a higher market cap than XOMA($237M). XOMA YTD gains are higher at: -24.619 vs. RCUS (-51.847). XOMA has higher annual earnings (EBITDA): -18.71M vs. RCUS (-269M). RCUS has more cash in the bank: 978M vs. XOMA (143M). RCUS has less debt than XOMA: RCUS (60M) vs XOMA (119M). RCUS has higher revenues than XOMA: RCUS (258M) vs XOMA (9.71M).
RCUSXOMARCUS / XOMA
Capitalization759M237M320%
EBITDA-269M-18.71M1,437%
Gain YTD-51.847-24.619211%
P/E RatioN/AN/A-
Revenue258M9.71M2,657%
Total Cash978M143M684%
Total Debt60M119M50%
FUNDAMENTALS RATINGS
RCUS vs XOMA: Fundamental Ratings
RCUS
XOMA
OUTLOOK RATING
1..100
5320
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
1
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
9483
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XOMA's Valuation (1) in the Biotechnology industry is somewhat better than the same rating for RCUS (57) in the Pharmaceuticals Major industry. This means that XOMA’s stock grew somewhat faster than RCUS’s over the last 12 months.

XOMA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that XOMA’s stock grew similarly to RCUS’s over the last 12 months.

XOMA's SMR Rating (97) in the Biotechnology industry is in the same range as RCUS (97) in the Pharmaceuticals Major industry. This means that XOMA’s stock grew similarly to RCUS’s over the last 12 months.

XOMA's Price Growth Rating (83) in the Biotechnology industry is in the same range as RCUS (94) in the Pharmaceuticals Major industry. This means that XOMA’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as XOMA (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to XOMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCUSXOMA
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 30 days ago
81%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SDGCX77.65N/A
N/A
DWS Capital Growth C
RYCHX138.42N/A
N/A
Rydex Technology C
NRECX14.27N/A
N/A
Neuberger Berman Real Estate C
PGBHX44.65N/A
N/A
Principal Blue Chip R6
VAPPX18.93N/A
N/A
VALIC Company I Capital Appreciation

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with APGE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then APGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
-9.13%
APGE - RCUS
43%
Loosely correlated
-7.51%
ACLX - RCUS
42%
Loosely correlated
-7.12%
ATXS - RCUS
41%
Loosely correlated
-6.70%
IDYA - RCUS
40%
Loosely correlated
-4.77%
ITOS - RCUS
40%
Loosely correlated
-1.21%
More